This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Biopharma Vital Signs – Part 1: Reading the Room at BIO
As BIO 2026 approaches, industry experts weigh in on the conversations likely to dominate the floor – from AI and funding pressures to manufacturing readiness, regulatory uncertainty, and the challenge of turning innovation into real-world impact
06/19/2026
7 min read
